<DOC>
	<DOCNO>NCT02810704</DOCNO>
	<brief_summary>PEPPER randomize study compare three commonly use anticoagulant North America patient elect undergo primary revision hip knee joint replacement surgery . The anticoagulant compare enteric coat aspirin , low intensity warfarin , rivaroxaban .</brief_summary>
	<brief_title>Comparative Effectiveness Pulmonary Embolism Prevention After Hip Knee Replacement</brief_title>
	<detailed_description>PEPPER large pragmatic clinical trial inform patient choice balance risk tolerance individual face decision different drug strategy deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) prevention total hip ( THA ) knee ( TKA ) replacement . Indeed , clinical equipoise exist ethically support randomized trial great potential change current practice . We select three prophylaxis method represent current orthopaedic practice North America collectively account 80 % hip knee replacement ; ) enteric coat aspirin ( regimen low bleeding risk ; clinical PE all-cause mortality rate comparable intensive anticoagulant ) , b ) low intensity ( INR Target 2.0 ) warfarin ( time honor one common North American regimen ; low bleeding risk [ 1-2 % ] ) , c ) rivaroxaban , new oral direct Factor Xa inhibitor ( regimen low PE DVT rate higher bleeding risk [ 3-5 % ] ) . Prophylaxis continue 30 day , accordance clinical guideline , pneumatic compression utilized hospital conjunction treatment group . Each regimen commonly use contemporary practice , support observational clinical trial data , endorsed American College Chest Physicians ( ACCP ) American Academy Orthopaedic Surgeons ( AAOS ) guideline</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>1 . Males females 21 year age old ; 2 . Undergoing elective primary revision hip knee replacement ; 3 . Patient necessary mental capacity participate able comply study protocol requirement ; 4 . Patient pregnant ; 5 . Patient sign consent form ; 6 . Patient wiling randomized participate . 1 . Patient undergoing bilateral hip knee replacement ; 2 . No patient undergo total hip knee replacement enrol study prior hip knee replacement ; 3 . Women pregnant breastfeeding ; 4 . Patient chronic anticoagulation antiplatelet medication ; 5 . Patient concurrently enrol another active interventional clinical trial test drug intervention know believe interact aspirin , warfarin , rivaroxaban ; 6 . Patient contraindication two three prophylaxis regimen ; 7 . Documented gastrointestinal , cerebral , hemorrhage within 3 month operation ; 8 . A known diagnosis defective hemostasis past history clinical bleeding require transfusion treatment ; 7 ) A know condition thrombophilia proven diagnostic laboratory testing ; 9 ) An operative procedure involve eye , ear , central nervous system within one month ; 10 ) Severe uncontrolled hypertension systolic BP &gt; 220mmHg diastolic BP &gt; 120mmHg ; 11 ) An absolute body weight less 41 kilogram ( 90.4 lb ) baseline ; 12 ) Vulnerable patient population include prisoner , institutionalized individual , mentally handicap .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Anticoagulant</keyword>
	<keyword>Venous Thromboembolism</keyword>
	<keyword>Pulmonary Embolism</keyword>
	<keyword>Total Knee Arthroplasty</keyword>
	<keyword>Total Hip Arthroplasty</keyword>
</DOC>